Kornimate/medical-research-clean huggingface dataset:
effect of dynamic sitting on pain development

Conditions: Lower Back Pain

Summary: worksite based prolonged static sitting postures can cause musculoskeletal pain. while the development of pain increases due to the constant growth of digitalization at work, numerous interventions to reduce prolonged sitting periods have been created. the effects of such interventions have not yet been properly examined. thus, the "dynsit-pain" project was initiated to investigate the influence of dynamic sitting on the pain development of pain developers in office environments.

this clinical investigation is a prospective, randomized, controlled, counter-balanced, two-arm field study investigating the effect of dynamic sitting on musculoskeletal pain in office workers classified as pain developers. the study consists of a pre-screening visit and 4 assessment days / visits. during this pre-screening visit and after proving the study eligibility (inclusion / exclusion criteria), half of the study participants will randomly be allocated to one of the two study arms. depending on the arm allocation, participants will receive a dynamic (= intervention) or static (= control) office chair for 6 weeks. after a wash-out of at least 4 weeks the 6-week intervention resp. control will be switched. the randomization will be realized with opaque envelopes. overall participants will execute the identical assessments within the control and the intervention chair group. the wash-out phase between the control and the intervention periods will ensue identical baseline conditions for both chairs. the overall duration of study participation amounts to 16 weeks.

Eligibility criteria:
inclusion criteria: * signed informed consent * people aged between 18 and 65 years * people classified as pain developers (e.g., increase of pain of 10 mm on a 100 mm paper based visual analogue scale) determined by pre-screening * office workers * employment status: \> 30 h / week * sufficient german language skills (minimum b2 level) * table height of at least 63 cm at the main workplace exclusion criteria: * physical or mental limitations that aggravate dynamic sitting or using the interventional chair (e.g., wheel chair users, vestibular dysfunctions) * pregnancy * working in sitting posture for less than 20 hours per working week in the main workplace. * bodyweight over 110 kg and a body height over 195 cm * regular therapy or medication for pain

Keywords: sedentary behavior occupational diseases pain developer lower back pain office environments
infrazygomatic versus intranasal injection sphinopalatine ganglion blockade effect on surgical field in fess

Conditions: Nasal Polyps

Summary: this study aimed to show the effect of sphinopalatine ganglion blockade on surgical field, hemodynamics and postoperative pain in fees operation.

functional endoscopic sinus surgery (fess) is a minimally invasive, effective surgical technique that is commonly used to treat chronic rhino sinusitis and nasal polyposis. intra-operative bleeding obscures the surgical view and increases the likelihood of iatrogenic complications. there are many factors that can affect the amount of bleeding experienced during surgery including both patient and surgical factors. these include severe forms of chronic sinusitis with nasal polyposis which is associated with increased vascularity, use of anticoagulant therapy, bleeding disorders, active infection, vascular tumor on the surgical site and revision surgery may affect bleeding on surgical site. sphenopalatine ganglion (spg) is the main sensory innervation to the nasal mucosa. the sphenopalatine ganglion block (spgb) is one of the regional anesthetic techniques that were used effectively before removal of nasal packing and in patients undergoing endoscopic sinus surgery under general anaesthesia to control bleeding or for postoperative analgesia

Eligibility criteria:
inclusion criteria: * patients of asa physical status i-ii. exclusion criteria: * patients of asa physical status iii or above. * patients with clinically significant cardiovascular, pulmonary or hepatic disease. * patients with bleeding diathesis or on anticoagulant therapy. * age less than 21 years. * mentally disabled patients.
tele-pharmacy intervention to improve treatment adherence

Conditions: Hyperlipidemia; Diabetes; Hypertension

Summary: the purpose of this cluster randomized controlled trial is to evaluate whether a novel tele-pharmacist-based intervention for patients with hyperlipidemia, hypertension, and diabetes improves medication adherence, disease control, and patients' understanding of their treatment.

long-term adherence to evidence-based medications remains exceptionally poor. half of all patients become non-adherent within a year of treatment initiation. interventions that improve medication adherence may have important clinical benefits across large populations, and may even be cost-saving by reducing rates of costly and morbid clinical outcomes such as myocardial infarction and stroke. the study of a tele-pharmacy intervention for chronic diseases to improve treatment adherence (stic 2 it) is a cluster randomized controlled trial (rct) evaluating whether a novel tele-pharmacist-based intervention improves medication adherence and disease control among individuals with hyperlipidemia, hypertension, and diabetes who are nonadherent to their medications and who have poor or worsening disease control. the intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. based on the barriers identified during the consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes. potentially eligible patients will be identified using data from paid-prescription claims data and the electronic health record. the study is being conducted at 14 practice sites in a large multi-specialty group practice with approximately 250 primary care physicians. practice sites will be randomized to intervention or control. in intervention sites, the primary care physicians of potentially eligible patients will be asked whether they would like patients to be enrolled in the intervention.

Eligibility criteria:
inclusion criteria: * filled and poorly adherent (defined as a pdc \< 80%) to medication for hyperlipidemia, hypertension, or diabetes * suboptimal average adherence to all of the qualifying medications that a patient has filled (defined as combined (average of averages) pdc \< 80%) * for patients with hypertension or diabetes, poor or worsening disease control (according to relevant clinical targets) exclusion criteria: * patients with \<6 months of continuous enrolment in the health plan * patients with no available contact information

Keywords: medication non-adherence hyperlipidemia diabetes hypertension
combination gemcitabine, carboplatin with or without trastuzumab in patients with metastatic breast cancer

Conditions: Breast Cancer

Summary: pre-clinical data suggests that combination therapy with gemcitabine and carboplatin is synergistic, and both drugs may be synergistic with trastuzumab. additionally, recent clinical data suggest that the combination of gemcitabine with platinum is an active regimen in metastatic breast cancer. this study will test the combination of gemcitabine with carboplatin in patients with metastatic breast cancer. patients with her2/neu overexpression will be stratified to receive trastuzumab in addition to gemcitabine and carboplatin.

upon determination of eligibility, all patients will receive the following treatment: gemcitabine + carboplatin

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * locally advanced or metastatic breast cancer * measurable disease as per recist criteria * no prior chemotherapy in the metastatic breast setting * prior chemotherapy and/or hormonal therapy for early stage breast cancer * adjuvant herceptin is allowed * prior radiation therapy in either the metastatic or early stage setting * patients may have received any number of hormonal therapies * age \>18 years * only women are eligible for the study * able to perform activities of daily living with minimal assistance * normal organ and bone marrow function * patients who will be receiving trastuzumab must have normal heart function * sign a written informed consent document exclusion criteria: you cannot participate in this study if any of the following apply to you: * received prior chemotherapy for metastatic breast cancer * known leptomeningeal carcinomatosis * uncontrolled brain metastasis * uncontrolled intercurrent illness * pregnant or lactating * history of other non-breast cancer malignancy * received prior chemotherapy for early stage breast cancer within 6 months please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
study of cd160, an activating nk cell receptor, in melanoma: a potential therapeutic target?

Conditions: Melanoma

Summary: although immunotherapy revolutionized melanoma outcomes over the last 10 years, only 40-50% of patients respond to treatments and 25% develop acquired resistances. natural killer (nk) cells naturally recognize and kill tumor cells. however, the immunosuppressive micro-environment generated by the tumor decreases nk cells' killing activity. cd160 is a nk cell receptor identified and characterized in our laboratory. engagement of the gpi isoform (cd160-gpi) initiates nk cell cytotoxic response. upon nk cell activation, a transmembrane isoform (cd160-tm) is neo-synthesized which promotes the amplification of activated nk cell cytotoxicity. the aim of this study is to assess the phenotypic profile of advanced stages melanoma patients' nk cells (mainly cd160-tm expression or its induction) and therefore the therapeutic potential of the use of an anti-cd160-tm agonist antibody to boost the nk-dependent mechanism leading to tumor depletion.


Eligibility criteria:
inclusion criteria : * patients aged18-years old or over * ecog score between 0-2 * inoperable stage iii or stage iv melanoma * naïve of treatment or in progression after one or several treatment lines * give their written consent for the present study and be included in melbase cohort. * health insurance coverage. supplementary inclusion criteria for part ii : * skin or subcutaneous melanoma lesions * agree and inform consent for a cutaneous biopsy or a tumor sample if presenting lymph nodes involvement if part of the usual clinical practice. exclusion criteria: * pregnant and breastfeeding women * patients with psychiatric disorders * patients already included in another clinical trial * having received chemotherapy or radiotherapy during the last 4 weeks, * patient presenting another solid or blood cancer, chronic viral infection (e.g. hiv, hbv or hcv) * been treated with more than 10mg of steroids until the 4 weeks before inclusion. * refusal to participate to the study * patients under guardianship or curatorship * patients on state medical aid
study of oral vorinostat in combination with topotecan in patients with chemosensitive recurrent sclc

Conditions: Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven diagnosis of sclc; * limited or extensive-stage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of first-line chemotherapy (sensitive relapse); * age \>/= 18 years; * ecog performance status 0-2; * life expectancy of at least 12 weeks; * measurable lesions according to recist criteria; * adequate cardiac, hepatic, renal, and bone marrow function; * written informed consent. exclusion criteria: * prior treatment with an hdac inhibitor; * symptomatic and/or unstable pre-existing brain metastases; * superior vena cava syndrome; * spinal cord compression; * severe or uncontrolled medical diseases (hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections); * other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ; * pregnant or breastfeeding women.

Keywords: second line chemotherapy
classification of stanford for snore as factor of aggravation of the apnea hypopnea index (aih) in patients with obstructive sleep apnea syndrome (osas)

Conditions: Obstructive Sleep Apnea Syndrome

Summary: introduction: obstructive sleep apnea syndrome (osas) became an important and prevalent illness in recent years. the population occidental becomes fat each time, and this symptom is associated the biggest risk for the osas. snore presence is extremely associated with osas. snoring is present in about 90 - 95% of the patients with osas. objectives: evaluate the influence in the stanford classification as predictor factor of gravity of the osas. materials and methods: they evaluated and classified 107 patients, classification of mallampati, friedman, classification of stanford and how much the gravity of the osas for the aih.


Eligibility criteria:
inclusion criteria: * not exhibiting any exclusion criteria * age \> 21 years exclusion criteria: * nasal tumor * bmi \>40 * nasal polipose * no acceptance of study

Keywords: classification of stanford for snoring osas apnea-hipopnea index
covid-19 with convalescent plasma

Conditions: COVID-19 Convalescent Plasma Treatment

Summary: to clarify the effects of convalescent plasma therapy on sars-cov-2 negative conversion rate during hospital stay and 28-day mortality of severe and life-threatening covid-19 patients.


Eligibility criteria:
inclusion criteria: 1. \> 18 years of age; 2. laboratory-confirmed diagnosis of covid-19; 3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal cannula\[hfnc\], noninvasive mechanical ventilation \[niv\], and invasive mechanical ventilation \[imv\]). exclusion criteria: * no

Keywords: convalescent plasma therapy covid-19 mortality
prevention of myopia of prematurity by calcium supplementation

Conditions: Myopia

Summary: the purpose of this study is to determine if supplementation of calcium by the enteral route (gut feeding) to extremely low birth weight infants will lead to less myopia (nearsightedness) at 6-12 months postnatal age. secondly, the study will determine if calcium supplementation is well tolerated, if it reduces the molding of these premature infants' heads, and if it decreases myopia at the 18-22 month postnatal age visit.

all infants admitted meeting the 401-1000gm birthweight and less than 14 day of age entry criteria will be screened for entry into the study. infants may be excluded for the following: major congenital malformations, including complex congenital heart disease (except open ductus arteriosus, atrial and ventricular septal defects), pulmonary malformations, bowel or anal stenosis or atresia, renal dysplasias, chromosomal anomalies, hydrops fetalis, bowel perforation or necrotizing enterocolitis stage 2a or greater before randomization. written informed consent of one parent or legal guardian must be obtained. the infants are randomized to receive unsupplemented feedings of breast milk or formula, or feedings supplemented with ca-gluconate as outlined below. randomization will be stratified into the following groups: 401-750 g and 751-1000 g and performed according to a balanced block scheme with variable block size (2-6) using sealed opaque envelopes. total parenteral nutrition is given by nursery unit standards. infant positioning is done by nursery unit standards. feeding mixtures: supplementation is started when enteral feeding amounts to 100 ml/kg. at that time, fortification is also introduced in infants receiving breast milk. fortified human milk or 24 cal/oz formula, e.g. similac special care 24 (ssc24), is used in all participating infants. human milk is fortified with 1 pk enfamil human milk fortifier per 25 ml (bmhmf). control group: fortified human milk or 24 cal/oz formula. supplemented group: ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons (e.g. rubbermaid (r)) and added to the feeding mixtures. one eye exam will be performed at 6-12 months during routine follow-up visit. a second eye exam will be performed at 18-2 months during a follow-up visit which is part of the nichd newborn follow-up clinic. head measurements, specifically, front-to-back and side-to-side will be measured at randomization, 36 weeks postmenstrual age or discharge, whichever occurs first, and during the follow up visits. urinalysis will be collected weekly.

Eligibility criteria:
inclusion criteria: * infants with a birthweight of 401 - 1000 g and postnatal age less than 14 days exclusion criteria: * major congenital malformations including * complex congenital heart disease (except open ductus arteriosus, atrial and ventricular septal defects) * pulmonary malformations * bowel or anal stenosis or atresia * renal dysplasias * chromosomal anomalies * hydrops fetalis * bowel perforation or necrotizing enterocolitis stage 2a or greater before randomization.

Keywords: myopia calcium supplementation prematurity
rct on the effect of endometrial injury on ongoing pregnancy rate in subfertile women undergoing ivf

Conditions: Subfertility

Summary: implantation failure remains one of the major factors limiting success in ivf treatment. it was postulated that the local injury to endometrium induces secretions of cytokines and growth factors such as leukemia inhibitory factor, interleukin-11, and heparin-binding egf-like growth factor which enhance decidualisation and facilitate implantation. it may also up-regulate the gene expressions related to endometrial receptivity and optimize the endometrial development. in stimulated cycles, local injury to the proliferative endometrium has been postulated to delay endometrial development thereby inducing synchronicity between endometrium and embryo stage and facilitate implantation (zhou et al, 2008; almog et al, 2010; gnainsky et al, 2010) the aim of the study is to determine whether endometrial injury by endometrial biopsy in mid-secretory phase of the preceding cycle would improve the on-going pregnancy rate in subfertile women undergoing ivf treatment.

consecutive women attending subfertility clinic at queen mary hospital, university of hong kong who are scheduled for ivf treatment will be recruited. women who have normal uterine cavity will be randomized into study and control groups in 1 to 1 ratio according to a computer-generated randomization list. patients will be stratified according to the first or repeated cycle. for patients in the study group, in the cycle immediately preceding the scheduled ivf treatment, lh surge will be determined by daily serum lh level starting from 18 days before the next expected period. lh surge is defined as an elevation of lh to 2 times the level of the average of the previous 3 days and the absolute level of the lh should be more than or equal to 20 iu/l. women randomized into the study group will have endometrial biopsy performed by pipelle 7 days after the lh surge (lh+7) and they will be instructed to use non-hormonal means of contraception during that cycle. all patients will then proceed to ivf treatment in the next cycle as scheduled. they will receive standard ovarian stimulation according to the departmental protocol and have a maximum of two embryos replaced 2 days after the oocyte retrieval. on-going pregnancy rates between the two groups will be compared.

Eligibility criteria:
inclusion criteria: * undergoing ivf for tubal, unexplained or male factor subfertility * normal uterine cavity as shown on saline sonogram / hysteroscopy done at baseline exclusion criteria: * presence of hydrosalpinx * presence of endometrial polyp or fibroid distorting uterine cavity * ivf cycles carried out for preimplantation genetic diagnosis * use of donor gametes

Keywords: endometrial injury pipelle implantation ongoing pregnancy rate ivf
stretch-shortening cycle exercise: potential implications for children with obstetric brachial plexus injury

Conditions: Erb Palsy

Summary: this study was set out to evaluate the effect of a 12-week stretch-shortening cycle exercise (ssc-ex) on muscle strength, bone mineral density, and upper extremity function in children with obstetric brachial plexus injury (obpi). fifty-six patients with obpi were randomly allocated to the ssc-ex group (n = 28, received ssc-ex program, twice/week, over 12 weeks) or the control group (n = 28, received standard exercise program). both groups were assessed for muscle strength, bone health, and upper extremity function before and after treatment.

fifty-six children with obpi were recruited from the physical therapy outpatient clinic of prince sattam bin abdulaziz university and three referral hospitals in riyadh provenience, saudi arabia. the study included children who had a confirmed diagnosis of upper arm type of obpi, classified as level i or ii per narakas classiﬁcation system, aged 10-16 years, had a functional level of grade iii according to the mallet scoring system, and were consuming a balanced diet. children who had a history of corrective neuromotor or musculoskeletal surgery, shoulder dislocation/subluxation, calcium supplements, or cognitive issues were excluded. outcome measures 1. muscle strength: the peak isometric muscle strength of the shoulder flexors, abductors, external rotators, elbow flexors, and extensors was measured using a hand-held dynamometer. 2. bone mineral properties: bone mineral density and bone mineral content of the humeral, radial, and ulnar shafts were measured through dual-energy x-ray absorptiometry (dexa) scanning. 3. upper-extremity function: the functional performance was assessed using the brachial plexus outcome measure (bpom) activity scale. the ssc-ex group received a 12-week therapist-led ssc-ex training, for approximately 35 minutes per session, two times a week for 12 consecutive weeks, in conformity with the national strength and conditioning association guidelines and american academy of pediatrics safety standards. the ssc-ex program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities. the ssc-ex program preceded with a warm-up for 5 minutes and ended with a cool-down for 5 minutes. the control group received the standard exercise program, 35 minutes per session, two times a week for 12 consecutive weeks. the program consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, manual guidance, and functional training.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of upper arm type of obpi. * narakas classiﬁcation level i or ii. * functional level of grade iii per the mallet scoring system. * age between 10-16 years. exclusion criteria: * history of neuromotor or musculoskeletal surgery. * shoulder subluxation/dislocation. * past fracture involving the upper extremities. * calcium supplement intake. * inability to adhere to the scheduled program.